ワークショップ11 免疫チェックポイント阻害剤

[WS11-4] Nivolumab+platinum chemotherapy+bevacizumab in advanced Non-SQ NSCLC：TASUKI-52 Final update

^○Kazuhiko Nakagawa¹, Jong-Seok Lee², Shunichi Sugawara³, Jin Hyoung Kang⁴, Hye Ryun Kim⁵, Naoki Inui⁶, Toyoaki Hida⁷, Ki Hyeong Lee⁸, Tatsuya Yoshida⁹, Hiroshi Tanaka¹⁰, Cheng-Ta Yang¹¹, Takako Inoue¹², Makoto Nishio¹³, Tomohide Tamura¹⁴, Nobuyuki Yamamoto¹⁵, Chong-Jen Yu¹⁶, Hiroaki Akamatsu¹⁵, Shigeru Takahashi¹⁷, Yuichiro Ohe⁹ (1.Department of Medical Oncology, Kindai University Faculty of Medicine, 2.Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 3.Department of Pulmonary Medicine, Sendai Kousei Hospital, 4.Department of Medical Oncology, The Catholic University of Korea, Seoul St. Mary's Hospital, 5.Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 6.Department of Pulmonary Medicine, Hamamatsu University Hospital, 7.Department of Thoracic Oncology, Aichi Cancer Center, 8.Department of Internal Medicine, Chungbuk National University Hospital, 9.Department of Thoracic Oncology, National Cancer Center Hospital, 10.Department of Internal Medicine, Niigata Cancer Center Hospital, 11.Department of Thoracic Medicine, Chang Gung Memorial Hospital, 12.Department of Thoracic Oncology, Osaka International Cancer Institute, 13.Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 14.Thoracic Center, St. Luke's International Hospital, 15.Internal Medicine III, Wakayama Medical University, 16.Department of Internal Medicine, National Taiwan University Hospital, 17.Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., LTD.)